Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
CMC BWG Case Study
Share |
 CMC_Biotech_Working_Group_Consortium

A consortium of the companies shown above, collectively known as the CMC-Biotech Working Group (CMC-BWG), has prepared a case study on the development of a monoclonal antibody. To view the entire case study please click here. The case study is intended to stimulate discussion between regulatory authorities and industry on the application of Quality by Design to products of biotechnology. CASSS has joined forces with the individuals of the consortium to promote and disseminate the case study.
  
The case study is not a mock submission, nor a gold standard defining the content of future regulatory submissions, and is not intended to be reviewed for approvability. The case study presents some novel ideas, and aspirational approaches that could be achieved when the principles of QbD are fully embraced.  This marks a significant opportunity to expand the discussion in the biotechnology community on the implementation of the advanced concepts of QbD. 
 
In addition to highlighting the case study here on our web site, we have plans to use it extensively around the world in discussions with industry and regulators throughout 2010 and beyond.  Look for sessions in the programs of the CMC Forum Europe (April 2010) and CMC Strategy Forum (July 2010) as well other workshops to be announced focusing on the A-Mab Case Study.
 


Biotech Working Group Team Members Only - Click Here
    
    

more Calendar

12/8/2014 » 12/9/2014
CMC Strategy Forum Japan 2014

1/26/2015 » 1/29/2015
CMC Strategy Forum and WCBP 2015

3/17/2015 » 3/20/2015
AT Europe 2015 Exhibitor Sign-Up

Featured Members
Brian K. Nunnally, Biogen Idec Inc.Brian has been a leader within CASSS for many years. This year he is the WCBP 2015 Co-Chair.

Membership Software Powered by YourMembership.com®  ::  Legal